PKI-166 hydrochloride
Based on 1 publication(s) in Google Scholar
PKI-166 hydrochloride is a potent, selective and orally active EGFR tyrosine kinase inhibitor, with an IC50 of 0.7 nM.
For research use only. We do not sell to patients.
- CAS No.: 2230253-82-2
- Formula: C20H19ClN4O
- Molecular Weight:366.84
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) PKI-166 hydrochloride
MoreAll EGFR Isoforms
More
Biological Activity
IC50: 0.7 nM (EGFR tyrosine kinase)[1]
PKI-166 hydrochloride (0-0.5 μM; 1 hour; pretreatment) inhibits EGFR autophosphorylation in human pancreatic cancer cells[1].
PKI-166 hydrochloride (0.03 μM; 6 days) enhances the cytotoxicity mediated by gemcitabine[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:L3.6pl cells
-
Concentration:0.01 μM, 0.05 μM, 0.5 μM
-
Incubation Time:1 hour
-
Result:Inhibited EGFR autophosphorylation in a dose-dependent manner.
-
Cell Line:L3.6pl cells
-
Concentration:0.03 μM
-
Incubation Time:6 days
-
Result:Enhanced the cytotoxicity mediated by gemcitabine.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male athymic nude mice with L3.6pl cells xenograft (8-12 weeks)[1]
-
Dosage:100 mg/kg
-
Administration:Oral administration; daily; for 29 days
-
Result:Significantly decreased median tumor volume.
Chemical Information
-
CAS No. 2230253-82-2
-
Molecular Weight 366.84
-
Formula C20H19ClN4O
-
SMILES
OC1=CC=C(C2=CC3=C(N=CN=C3N2)N[C@H](C)C4=CC=CC=C4)C=C1.Cl[H]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PKI-166 hydrochloride Related Classifications
HY-110328 Related Classifications
Powered by Bioz